Using In Silico Methods to Identify Protein Tyrosine Kinase A (PtkA) Homolog in Non-Tuberculous Mycobacteria (NTM) by Swati Jaiswal, Sanjay Kumar

Subjects: Get full text

Therapeutic effect of selective interleukin-2-inducible tyrosine kinase inhibitor in orbital fibroblasts from patients with Graves’ orbitopathy by Yeonjung Yoon, Hyun Young Park, Min Kyung Chae, Sun Young Jang, Jin Sook Yoon

Subjects: “…interleukin-2 inducible tyrosine kinase…”
Get full text

Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib by Vineeth Sukrithan, Lisa Kim, Jennifer A. Sipos, Ashima Goyal, Ye Zhou, Daniel Addison, Manisha Shah, Bhavana Konda, Ajay Vallakati

“…The multitargeted tyrosine kinase inhibitor lenvatinib has demonstrated significant improvements in progression-free survival in RAIR thyroid cancers compared to placebos. …”
Get full text

Tyrosine Kinase-2, Angiopoietin-2, and Thrombomodulin Axes in the Late-Onset Fetal Growth Restriction: A Prospective Cohort Study by Esra Altan Erbilen, Fusun Gulizar Varol

Subjects: Get full text

Retraction: X-linked immunodeficient mice with no functional Bruton’s tyrosine kinase are protected from sepsis-induced multiple organ failure by Frontiers Editorial Office

Get full text

Activating Mutation (V617F) in the Tyrosine Kinase JAK2 is Absent in Locally-Confined or Castration-Resistant Prostate Cancer by Lei Gu, Xian-Hua Zhu, Tapio Visakorpi, Kalle Alanen, Tuomas Mirtti, Tina Bocker Edmonston, Marja T. Nevalainen

“…The receptor-associated tyrosine kinase Jak2 is a known key activator of Stat5a/b in prostate cancer cells in response to ligand stimulation. …”
Get full text

Cell-free expression and SMA copolymer encapsulation of a functional receptor tyrosine kinase disease variant, FGFR3-TACC3 by Alexander J. D. Snow, Tharushi Wijesiriwardena, Benjamin J. Lane, Brendan Farrell, Polly C. Dowdle, Matilda Katan, Stephen P. Muench, Alexander L. Breeze

“…The inherent enzymatic activity of receptor tyrosine kinases (RTKs) presents additional challenges. …”
Get full text

Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax by Caroline A. Coughlin, Dhanvantri Chahar, Marianna Lekakis, Abdessamad A. Youssfi, Lingxiao Li, Evan Roberts, Natalia Campos Gallego, Claude-Henry Volmar, Ola Landgren, Shaun Brothers, Anthony J. Griswold, Catalina Amador, Daniel Bilbao, Francesco Maura, Jonathan H. Schatz

“…Here, we build on recent findings implicating gain-of-function mutations in the BCL10 signaling protein as drivers of resistance to Bruton’s tyrosine kinase (BTK) inhibitors. We show mutant BCL10-driven DLBCL is resistant to multiple additional drug classes, demonstrating urgency to derive mechanistically rooted strategies to overcome undruggable BCL10 mutants that stabilize BTK-independent signaling filaments upstream of NF-kB activation. …”
Get full text

Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia by Carmen Rădulescu, Anca Bacârea, Adina Huțanu, Rozalia Gabor, Minodora Dobreanu

Get full text

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials by José Pinto-Fraga, Celia García-Chico, Simone Lista, Pedro Miguel Lacal, Giuseppe Carpenzano, Maurizio Salvati, Alejandro Santos-Lozano, Grazia Graziani, Claudia Ceci

Subjects: Get full text

An Elevated Maternal Plasma Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at Midtrimester Is a Useful Predictor for Preeclampsia by Mahmoud Fathy Hassan, Nancy Mohamed Ali Rund, Ahmed Husseiny Salama

Get full text

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia by Melea A. Ward, Gang Fang, Kristy L. Richards, Christine M. Walko, Stephanie R. Earnshaw, Laura E. Happe, Susan J. Blalock

“…**Objectives:** This study assessed the comparative rates of treatment interruption and regimen change between patients initiating first-line therapy with a first-generation tyrosine kinase inhibitor (1GTKI) imatinib versus second-generation TKI (2GTKI), dasatinib or nilotinib, for the treatment of CML in clinical practice. …”
Get full text

Contralateral Renal Cell Carcinoma Ureteric Metastases Can Arise on Tyrosine Kinase Adjuvant Therapy and Be Effectively Treated by Endoscopic Laser Excision and Ablation by Sarah L. Reid, Nikolas J. Arestis, Craig McIlhenny, Gavin W. A. Lamb

Get full text

Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor by T. D. de Gruijl, G. Giaccone, R. J. Scheper, H. van Cruijsen, K. Hoekman, B. C. Kuenen, A. J. M. van den Eertwegh, A. G. M. Stam

Get full text

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia by Xiaoxia Wu, Shenqi Lu, Xinhui Zhang, Zhen Yang, Aining Sun, Depei Wu, Huifen Zhou, Miao Miao

Subjects: Get full text

The Lck Paradox: Because of Inconsistent Experimental Evidence, the Role of the Protein Tyrosine Kinase p56lck in Early Thymic Development Remains Poorly Defined by Klaus Eichmann

Get full text

Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors by Linan Yin, Ruibao Liu, Wei Li, Shijie Li, Xunbo Hou

“…Abstract Objective To develop and validate a computed tomography (CT)-based deep learning radiomics model to predict treatment response and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (uHCC) treated with transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors and tyrosine kinase inhibitors (TKIs). Methods This retrospective study included 172 patients with uHCC who underwent combination therapy of TACE-HAIC with TKIs and PD-1 inhibitors. …”
Get full text

Combined Effects of 2-Methoxyestradiol (Hypoxia-Inducible Factor 1α Inhibitor) and Dasatinib (A Second-Generation Tyrosine Kinase Inhibitor) on Chronic Myelocytic Leukemia Cells by Yuexian Zhang, Heng Chen, Yunfeng Shen, Xin Zhou

Get full text

Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience by Jwa Hoon Kim, Min‐Hee Ryu, Changhoon Yoo, Heejung Chae, Hana Na, Moyoul Beck, Beom Su Kim, Moon‐Won Yoo, Jeong Hwan Yook, Byung Sik Kim, Ki‐Hun Kim, Chan Wook Kim, Yoon‐Koo Kang

“…Abstract The long‐term effects of tyrosine kinase inhibitors (TKIs), including imatinib, and surgical intervention on advanced gastrointestinal stromal tumor (GIST) were evaluated. …”
Get full text

Vitamin K‐dependent gamma‐carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosine kinase receptor EGFR by Zheng Wu, Qing Ye, Shan Zhang, Li‐Peng Hu, Xiao‐Qi Wang, Lin‐Li Yao, Lei Zhu, Shu‐Yu Xiao, Zong‐Hao Duan, Xue‐Li Zhang, Shu‐Heng Jiang, Zhi‐Gang Zhang, De‐Jun Liu, Dong‐Xue Li, Xiao‐Mei Yang

Get full text